These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37095347)

  • 81. Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery.
    van Rijn CJM; Vlaming KE; Bem RA; Dekker RJ; Poortinga A; Breit T; van Leeuwen S; Ensink WA; van Wijnbergen K; van Hamme JL; Bonn D; Geijtenbeek TBH
    Sci Rep; 2023 May; 13(1):8851. PubMed ID: 37258559
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2.
    Huang H; Zhang C; Yang S; Xiao W; Zheng Q; Song X
    J Control Release; 2021 Jul; 335():449-456. PubMed ID: 34029632
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.
    Rice A; Verma M; Voigt E; Battisti P; Beaver S; Reed S; Dinkins K; Mody S; Zakin L; Tanaka S; Morimoto B; Olson CA; Gabitzsch E; Safrit JT; Spilman P; Casper C; Soon-Shiong P
    Front Immunol; 2022; 13():910136. PubMed ID: 35911728
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment.
    Malladi SK; Singh R; Pandey S; Gayathri S; Kanjo K; Ahmed S; Khan MS; Kalita P; Girish N; Upadhyaya A; Reddy P; Pramanick I; Bhasin M; Mani S; Bhattacharyya S; Joseph J; Thankamani K; Raj VS; Dutta S; Singh R; Nadig G; Varadarajan R
    J Biol Chem; 2021; 296():100025. PubMed ID: 33154165
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.
    Ying B; Whitener B; VanBlargan LA; Hassan AO; Shrihari S; Liang CY; Karl CE; Mackin S; Chen RE; Kafai NM; Wilks SH; Smith DJ; Carreño JM; Singh G; Krammer F; Carfi A; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    Sci Transl Med; 2022 Feb; 14(630):eabm3302. PubMed ID: 34846168
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021.
    Moline HL; Keaton A; Rice W; Varghese J; Deng L; Waters A; Barringer A; Winston D; Fields V; Slifka KJ; Verani JR; Schrag SJ; Jernigan J; Tate JE; Fleming-Dutra KE
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S155-S158. PubMed ID: 35758873
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    Stowe J; Miller E; Andrews N; Whitaker HJ
    PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines.
    Lim JME; Hang SK; Hariharaputran S; Chia A; Tan N; Lee ES; Chng E; Lim PL; Young BE; Lye DC; Le Bert N; Bertoletti A; Tan AT
    Cell Rep Med; 2022 Nov; 3(11):100793. PubMed ID: 36257326
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients.
    Holden IK; Bistrup C; Nilsson AC; Hansen JF; Abazi R; Davidsen JR; Poulsen MK; Lindvig SO; Justesen US; Johansen IS
    J Intern Med; 2021 Dec; 290(6):1264-1267. PubMed ID: 34237179
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.
    Luczkowiak J; Rivas G; Labiod N; Lasala F; Rolo M; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Med Virol; 2023 Jan; 95(1):e28268. PubMed ID: 36319593
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Sequence-Optimized mRNA Vaccines Against Infectious Disease.
    Rauch S; Lutz J; Mühe J; Kowalczyk A; Schlake T; Heidenreich R
    Methods Mol Biol; 2024; 2786():183-203. PubMed ID: 38814395
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Strategies to reduce the risks of mRNA drug and vaccine toxicity.
    Bitounis D; Jacquinet E; Rogers MA; Amiji MM
    Nat Rev Drug Discov; 2024 Apr; 23(4):281-300. PubMed ID: 38263456
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination.
    Suberi A; Grun MK; Mao T; Israelow B; Reschke M; Grundler J; Akhtar L; Lee T; Shin K; Piotrowski-Daspit AS; Homer RJ; Iwasaki A; Suh HW; Saltzman WM
    Sci Transl Med; 2023 Aug; 15(709):eabq0603. PubMed ID: 37585505
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Topical application of Lactobacilli successfully eradicates Pseudomonas aeruginosa biofilms and promotes wound healing in chronic wounds.
    Li Z; Zhang S; Zuber F; Altenried S; Jaklenec A; Langer R; Ren Q
    Microbes Infect; 2023; 25(8):105176. PubMed ID: 37406851
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination.
    Feng YX; Hu H; Wong YY; Yao X; He ML
    Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242591
    [TBL] [Abstract][Full Text] [Related]  

  • 100. New Vaccine Platforms-Novel Dimensions of Economic and Societal Value and Their Measurement.
    Buck PO; Gomes DA; Beck E; Kirson N; Mattera M; Carroll S; Ultsch B; Jayasundara K; Uhart M; Garrison LP
    Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.